The single protein-coding gene known as messenger ribonucleic acid (mRNA) is located in the genome and provides the basis for how cells make proteins. Mammalian cells are used in the laboratory to create mRNA vaccines and treatments, which have positive immunological properties. Some of the most common types of vaccines and therapies include non-replicating, in vivo self-replicating, self-amplifying, and in-vitro dendritic cell non-replicating mRNA. They are administered intravenously to trigger the immune system's virus-detection mechanisms and trigger the production of viral antigen proteins by the cells. The body's immunity is strengthened through enhancing B- and T-cell responses.
The major factors that drive the growth of the global mRNA vaccines and RNAi therapeutics market include increase in awareness about vaccination, increase in prevalence of cancer and cardiovascular disease and initiatives taken by government for large scale sequencing projects. In addition, target specialty and selectivity of treatment further propel the market growth. However, high cost of research, threat of failure and challenges in quantification of mRNA are expected to restrain the growth of the mRNA vaccines and RNAi therapeutics market during the forecast period. Conversely, application of mRNA technology and development of mRNA biomarker are anticipated to provide lucrative opportunities to the market players.
The mRNA vaccines and RNAi therapeutics market is segmented into disease type, route of administration, end user and region. According to disease type, the market is categorized into hereditary transthyretin-mediated amyloidosis genetic, acute hepatic porphyria, primary hyperoxaluria type 1 and atherosclerotic cardiovascular disease. On the basis of route of administration, it is segmented into IV infusion and subcutaneous. By end user, it is segregated into research institute and hospitals and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include the Alnylam Pharmaceuticals, BioNTech AG, CureVac AG, eTheRNA Immunotherapy, Ethris GmbH, In-Cell-Art, Moderna Therapeutics, Sangamon therapeutic Inc., Sanofi AG, SCM Lifescience Co., Ltd, Sarepta Therapeutics, Arcturus Therapeutics, Ionis pharmaceuticals Inc., Nutcracker Therapeutics, and TIBA Biotech.
The major factors that drive the growth of the global mRNA vaccines and RNAi therapeutics market include increase in awareness about vaccination, increase in prevalence of cancer and cardiovascular disease and initiatives taken by government for large scale sequencing projects. In addition, target specialty and selectivity of treatment further propel the market growth. However, high cost of research, threat of failure and challenges in quantification of mRNA are expected to restrain the growth of the mRNA vaccines and RNAi therapeutics market during the forecast period. Conversely, application of mRNA technology and development of mRNA biomarker are anticipated to provide lucrative opportunities to the market players.
The mRNA vaccines and RNAi therapeutics market is segmented into disease type, route of administration, end user and region. According to disease type, the market is categorized into hereditary transthyretin-mediated amyloidosis genetic, acute hepatic porphyria, primary hyperoxaluria type 1 and atherosclerotic cardiovascular disease. On the basis of route of administration, it is segmented into IV infusion and subcutaneous. By end user, it is segregated into research institute and hospitals and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include the Alnylam Pharmaceuticals, BioNTech AG, CureVac AG, eTheRNA Immunotherapy, Ethris GmbH, In-Cell-Art, Moderna Therapeutics, Sangamon therapeutic Inc., Sanofi AG, SCM Lifescience Co., Ltd, Sarepta Therapeutics, Arcturus Therapeutics, Ionis pharmaceuticals Inc., Nutcracker Therapeutics, and TIBA Biotech.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mRNA vaccines and RNAi therapeutics market analysis from 2021 to 2031 to identify the prevailing mrna vaccines and rnai therapeutics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the mRNA vaccines and RNAi therapeutics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global mRNA vaccines and RNAi therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Disease Type
- Hereditary transthyretin-mediated amyloidosis genetic
- Acute hepatic porphyria
- Primary hyperoxaluria type 1
- Atherosclerotic cardiovascular disease
By Route of administration
- IV infusion
- Subcutaneous
By End user
- Research Institutes
- Hospitals and clinics
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Alnylam Pharmaceuticals
- BioNTech AG
- Curevac AG
- Etherna Immunotherapies
- Ethris GMBH
- IN-CELL-ART
- Moderna Therapeutics
- Sangamo Therapeutics, Inc.
- Sanofi AG
- SCM Life Sciences (Argos Therapeutics, Inc. )
- Sarepta Therapeutics
- Arcturus Therapeutics
- Ionis Pharmaceuticals, Inc
- Nutcracker
- Tiba Biotech
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE
CHAPTER 5: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
CHAPTER 6: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER
CHAPTER 7: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “mRNA Vaccines and RNAi Therapeutics Market," the mRNA vaccines and RNAi therapeutics market was valued at $707.97 million in 2021, and is estimated to reach $12.31 billion by 2031, growing at a CAGR of 31.3% from 2022 to 2031.mRNA vaccines and RNAi therapeutics have tremendous potential to fight against cancer and viral diseases due to superiorities in safety, efficacy and industrial production. In recent decades, there has been development of different kinds of mRNAs by sequence optimization to overcome the disadvantage of excessive mRNA immunogenicity, instability and inefficiency. Based on the immunological study, mRNA vaccines and RNAi therapeutics are coupled with immunologic adjuvant and various delivery strategies. Except for sequence optimization, the assistance of mRNA-delivering strategies is another method to stabilize mRNAs and improve their efficacy. The understanding of increasing the antigen reactiveness gains insight into mRNA-induced innate immunity and adaptive immunity without antibody-dependent enhancement activity. Thus, to address the problem, scientists further exploited carrier-based mRNA vaccines (lipid-based delivery, polymer-based delivery, peptide-based delivery, virus-like replicon particle and cationic nano emulsion), naked mRNA vaccines and dendritic cell-based mRNA vaccines.
The key factors that drive the mRNA vaccines and RNAi therapeutics market growth is increase in prevalence of chronic disease and infectious disease, initiatives taken by government for large scale sequencing projects.
In addition, target specialty and selectivity of treatment and increasing awareness about vaccination are some mRNA vaccines and RNAi therapeutics market trends which further expected to boost the mRNA vaccines and RNAi therapeutics market size growth during forecast period. However, high cost of research, threat of failure and challenges in quantification of mRNA is expected to hamper the growth of the mRNA vaccines and RNAi therapeutics market during the forecast period. Conversely, applications of mRNA technology and development of mRNA biomarker are expected to provide numerous opportunities for market growth during the forecast period.
By disease type, the hereditary transthyretin-mediated amyloidosis genetic segment dominated the mRNA vaccines and RNAi therapeutics market share in 2021 and is expected to remain dominant during the forecast period. This is attributed to the rise in demand for the treatment of ATTR amyloidosis owing to, increase in prevalence and increasing need for the treatment of fatal disease. In addition, increase in awareness, improvement in diagnostic procedures, improvement in health care services, rapid economic growth in developing countries, and rise in R&D activities further boost the market growth. On the other side, Atherosclerotic cardiovascular disease is projected to exhibit the fastest market growth during the forecast period, owing to high consumption of cholesterol-lowering drugs by patients to reduce blockages in arteries.
Depending on route of administration, the IV infusion segment was the major revenue contributor in mRNA vaccines industry and RNAi therapeutics industry, and is anticipated to continue this trend during the forecast period, owing to increase in adoption of IV infusion for administration of vaccines and therapeutics. On the other side, subcutaneous segment is projected to exhibit the fastest market growth during the forecast period owing to cost effectiveness of subcutaneous route of administration as compare to IV infusion.
By end user, the hospitals & clinics segment dominated the market in 2021 and is expected to remain dominant during the forecast period, owing to increase in number of patients with respiratory disease, cancer and infectious disease. Furthermore, the research institutes segment is projected to show fastest growth during the forecast period, due to collaboration of research organizations and research institutes or collaborating with government bodies to bear the high cost of research.
Region wise, North America has the highest market share in 2021 registering a CAGR of 31.1% during the forecast period. This is attributed to the well-established healthcare system, increase in number of geriatric patients, and supportive reimbursement policies in healthcare system and increasing number of healthcare facilities offering mRNA vaccines and RNAi therapeutics. Asia-Pacific is projected to register the highest CAGR of 33.9% during the forecast period. The presence of a large population base, increasing per capita income, growing medical tourism industry, and rising public awareness regarding benefits of mRNA vaccine and RNAi therapeutics are the key driving factors that boost the growth of the market in the region.
Key Findings of the Study
- On the basis of disease type, the hereditary transthyretin-mediated amyloidosis genetic segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
- On the basis of route of administration, the IV infusion segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
- Depending on end user, hospitals and clinics segment is projected to grow at a CAGR of 31.6% during the forecast period.
- Region-wise, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 33.9% during the forecast period.
Companies Mentioned
- Alnylam Pharmaceuticals
- Biontech AG
- Curevac AG
- Etherna Immunotherapies
- Ethris GmbH
- In-Cell-Art
- Moderna Therapeutics
- Sangamo Therapeutics, Inc.
- Sanofi AG
- Scm Life Sciences (Argos Therapeutics, Inc. )
- Sarepta Therapeutics
- Arcturus Therapeutics
- Ionis Pharmaceuticals, Inc
- Nutcracker
- Tiba Biotech
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
